Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.
about
Hematological toxicity of carboplatin for gynecological cancer according to body mass index.Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients.Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modellingModel Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.Opportunities for model-based precision dosing in the treatment of sickle cell anemia.Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine.Personalised dosing of medicines for children.Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.Dosing algorithm revisit for busulfan following IV infusion.Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.Predictive performance of a physiologically based pharmacokinetic model of busulfan in children.Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway.What is the best size predictor for dose in the obese child?Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?Critical Considerations in Anticancer Drug Development and Dosing Strategies: The Past, Present, and Future.Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.Why standards are useful for predicting doses.Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation.Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.Population Pharmacokinetics of the Antimalarial Amodiaquine: A Pooled Analysis to Optimize DosingEmerging roles for clinical pharmacometrics in cancer precision medicine
P2860
Q33432963-681B8104-6919-44C1-B5FE-A735A22057E0Q33687277-5D7B0F49-FA76-4EA4-94DF-B32C76DB70DCQ34409335-D791FDDF-DEA4-435E-B125-DE5D9C0ACBC5Q34571036-36A79DA2-6D50-4CC9-9545-716297E8F58AQ36203402-BB253ECC-6572-4D10-9E30-A95247CCC814Q36777485-CD2C150D-B0B5-4067-BD74-7566FC494937Q36892839-CE38042D-7AC0-4C0D-A59A-8F0CB7D28A74Q38262916-3EE2B6F3-099B-4381-81AA-8393A76D9AE1Q38642609-5591ADCE-391B-49CC-9303-1B3F22464630Q38674724-73451299-C44A-4BB8-BA8F-D3BD53EDDB81Q38749764-0410AFA4-5402-45B0-B4CC-05887C0EBAADQ38847841-08962A60-B5A7-4A7E-88AA-5B8771F179E0Q40085411-96808A85-7A1C-4005-A329-34F7C3A35C70Q40554814-968E0B71-9C65-4BD9-9FAE-532E75CD9F88Q41621632-752BA470-8568-4E9F-A956-81267FDF8837Q41653330-762A298D-7130-4E64-9857-769499755F78Q44419087-0D9BCE96-44A2-43DB-8959-9C1B8E724440Q47116870-B331FEB8-1F22-4EA3-B061-878381610242Q47179401-AA53B8AF-D4F8-4337-8354-8F11A8EBBD0FQ47313046-36919476-9A23-4861-90B0-F081A955A15AQ47943868-AD81B3D8-8AE5-41F0-B88E-77E02161662FQ47972996-0A70A036-FCB6-44EF-8A29-78FCBA53F4B9Q48333770-5272EFBE-FD1E-47C9-B87C-853CCB8ED799Q49171317-DA0E8761-9795-4EE0-B09C-190AF4ABE207Q50457678-EB243ABD-EE3A-4967-9E0F-3D75EC0561CEQ50924228-AD1B22FD-E171-4289-9ADF-18B35C5FB58FQ52690736-B6B5EB2A-7501-4009-A861-9AF568DB38DEQ56358106-CF576F9B-9B8D-4C50-9CE5-529A061ABD38Q57825305-8B6A38A7-1EB0-4B68-9471-8990B0D4FF05
P2860
Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Busulfan in infant to adult he ...... Bayesian dose personalization.
@en
Busulfan in infant to adult he ...... Bayesian dose personalization.
@nl
type
label
Busulfan in infant to adult he ...... Bayesian dose personalization.
@en
Busulfan in infant to adult he ...... Bayesian dose personalization.
@nl
prefLabel
Busulfan in infant to adult he ...... Bayesian dose personalization.
@en
Busulfan in infant to adult he ...... Bayesian dose personalization.
@nl
P2093
P2860
P1476
Busulfan in infant to adult he ...... Bayesian dose personalization
@en
P2093
Alan S Gamis
Jeffrey S Barrett
K Scott Baker
Meagan J Bemer
P2860
P304
P356
10.1158/1078-0432.CCR-13-1960
P407
P577
2013-11-11T00:00:00Z